id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-031518-1w14wr0i	Khodarahmi, Reza	The ACE2 as a “rescue protein” or “suspect enzyme” in COVID-19: possible application of the “engineered inactive hrsACE2” as a safer therapeutic agent in the treatment of SARS-CoV-2 infection	2020-09-07		.txt	text/plain	4651	190	42	The authors expressed that hrsACE2 can block early entry of SARS-CoV-2 infections in various host cells, especially alveolar epithelial type II cells, as a viral reservoir and stated that they cannot make any predictions with respect to the effect of the recombinant protein on the later stages of COVID-19 and, also, honestly mentioned the study limitations. Moreover, since ACE2 is expressed in various tissues including the heart, kidney tubules, the luminal surface of the small intestine and blood vessels [2] and references therein), SARS-CoV-2could also infect these tissues, so that clinically, SARS-CoV-2 has been found in the urine, and cardiovascular and renal dysfunctions have been reported for many patients with COVID-19. As mentioned above, patients with COVID-19 have significantly elevated levels of plasma angiotensin II compared to that of healthy individual and membrane-bound ACE2 (in addition to protecting from lung injury, based on its catalytic domain) is the critical in vivo SARS-CoV spike glycoprotein receptor.	./cache/cord-031518-1w14wr0i.txt	./txt/cord-031518-1w14wr0i.txt